<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4727">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01729702</url>
  </required_header>
  <id_info>
    <org_study_id>2008-08</org_study_id>
    <nct_id>NCT01729702</nct_id>
  </id_info>
  <brief_title>Neurohormonal Parameters in Hypertrophic Cardiomyopathies</brief_title>
  <acronym>REEF-CMH</acronym>
  <official_title>Evaluation at Rest and Exercise of Clinical, Ultrasonic and Neurohormonal Parameters in Hypertrophic Cardiomyopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Cardiology Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Cardiology Society</source>
  <oversight_info>
    <authority>France:Agence Nationale de Sécurité des Médicaments</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to demonstrate that changes in plasma levels of
      circulating neurohormones (mainly BNP and NT-proBNP), measured at rest and post-exercise
      correlate with exercise  functional limitation (assessed by exercise peak VO2) and exercise
      ultrasonic parameters (as left ventricular filling, obstruction, and mitral regurgitation)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary purposes are to study the kinetics of secretions of natriuretic peptides, and
      their relationships with extent of MRI myocardial fibrosis with the degree of exercise
      functional limitation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Plasmatic Neurohormonal measures: BNP - NT ProBNP - Troponine</measure>
    <time_frame>Day 1 at rest and during exercise</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy</condition>
  <condition>2- Obstructive Hypertrophic Cardiomyopathy</condition>
  <condition>3- Non Obstructive Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>single group - consecutive patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample collection</intervention_name>
    <arm_group_label>single group - consecutive patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Age 18 to 75 years

          -  Primary (sarcomeric) hypertrophic cardiomyopathy, obstructive or non obstructive,
             with studies of exercise peak oxygen consumption and cardiac MRI with gadolinium
             late-enhancement

          -  Informed consent

          -  Patient with a social insurance Patient at rest

          -  - Age 18 to 75 years

          -  Primary (sarcomeric) hypertrophic cardiomyopathy, obstructive or non obstructive

          -  Informed consent

          -  Patient with a social insurance

        Exclusion Criteria:

          -  - Insufficient echogenicity

          -  Permanent atrial fibrillation

          -  Complete BBB on the ECG

          -  LVEF &lt; 35 %

          -  Previous septal ablation (surgical or percutaneous)

          -  Simultaneous participation to another biomedical research

        If exercise needed:

          -  contraindication to exercise : hemodynamic instability, uncontrolled high blood
             pressure (&gt;220/120 mmHg), severe aortic stenosis

          -  Inability to exercise (muscular, pulmonary, elderly patient)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Hagège, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>HEGP - Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>November 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>1- Hypertrophic cardiomyopathy</keyword>
  <keyword>2- BNP</keyword>
  <keyword>3- NT-proBNP</keyword>
  <keyword>4- Neurohormons</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
